IV nivolumab

DRUG2 trials

Sponsors

Universitair Ziekenhuis Brussel, National Cancer Centre, Singapore

Conditions

Metastases to Soft TissueNK/T Cell LymphomaSolid Tumor

Phase 1

Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab

RecruitingNCT03707808

Universitair Ziekenhuis BrusselMetastases to Soft Tissue, Solid Tumor

Start: 2018-01-29End: 2025-12-24Target: 18Updated: 2025-01-20

Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma

WithdrawnNCT04230330

National Cancer Centre, SingaporeNK/T Cell Lymphoma

Start: 2019-12-12End: 2020-06-12Updated: 2020-11-05

Related Papers

A randomized phase II clinical trial on intratumoral autologous CD1c (BDCA-1) <sup>+</sup> /CD141 (BDCA-3) <sup>+</sup> myeloid dendritic cells (myDC) plus ipilimumab (IPI) and synthetic adjuvant AS01B combined with low-dose intravenous (IV) nivolumab (NIVO) in advanced pretreated melanoma patients.

Journal of Clinical Oncology2026-05-28

Intratumoral administration of the immunologic adjuvant AS01<sub>B</sub>in combination with autologous CD1c (BDCA-1)<sup>+</sup>/CD141 (BDCA-3)<sup>+</sup>myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma

Journal for ImmunoTherapy of Cancer2024-01-016 citations

790 Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)<sup>+</sup>/CD141 (BDCA-3)<sup>+</sup> myeloid dendritic cells plus ipilimumab and AS01<sub>B</sub> in combination with intravenously administered nivolumab

Regular and Young Investigator Award Abstracts2022-11-01

A phase Ib clinical trial on intratumoral administration of autologous CD1c (BDCA-1)<sup>+</sup> myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors.

Journal of Clinical Oncology2019-05-201 citations